Video

Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma

Author(s):

Narendranath Epperla, MBBS, MS

In Partnership With:

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

Related Videos
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Tracy George, MD
Elias Jabbour, MD
Bently P. Doonan, MD
Eytan M. Stein, MD
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Related Content
Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL
December 10th 2024

Axi-Cel Sustains Long-Term Efficacy in R/R Follicular Lymphoma and MZL

Alice Mims, MD, medical oncologist, associate professor, the Division of Hematology, The Ohio State University Comprehensive Cancer Center—James
February 26th 2024

Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL
December 10th 2024

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL

Matthew Lunning, DO, FACP
January 22nd 2024

Lunning and Maddocks Talk Through Frontline MCL Management

Diffuse Large B-cell Lymphoma | Image Credit: © Свет Лана – stock.adobe.com
December 8th 2024

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

Diffuse Large B-cell Lymphoma | Image Credit: © LASZLO – stock.adobe.com
December 8th 2024

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL